CV Sciences Certificate of Analysis



This document is to certify that units of the lot number below were tested and found to comply with CV Sciences finished product specifications.

SAMPLE ID:	PRODUCT NAME:
Strength:	
Lot Number:	
Expiration Date:	

CANNABINOIDS*	MG/UNIT	METHOD
CBD		
CBDA		
d9-THC		
THCA-A		
d8-THC		
ТНСУ		
CBDV		
CBDVA		
CBGA		
CBG		
CBN		
CBC		
CBL		
Total Cannabinoids		
Sample Size		
THC by Mass		

HEAVY METALS*	STATUS (PASS/FAIL)	METHOD
Arsenic		
Cadmium		
Mercury		
Lead		

Docusign Envelope ID: 11DA3FBB-CC1C-4B5F-A7BE-5E03E92AE270

CV Sciences Certificate of Analysis



MICROBIOLOGY*	STATUS (PASS/FAIL)	METHOD
Mold/Mildew/Yeast		
Aerobic Bacteria		
Coliforms		
E. Coli		
Salmonella		
Pseudomonas		

PESTICIDES**	STATUS (PASS/FAIL)	METHOD
Total Pesticides		
Mycotoxins	Pass	
RESIDUAL SOLVENTS**	STATUS (PASS/FAIL)	METHOD
Total Residual Solvents		

- 1. The hemp extract is the product of a batch tested by the independent testing laboratory;
- 2. The batch contained a total delta-9-tetrahydrocannabinol concentration that did not exceed 0.3 percent pursuant to the testing of random sample of the batch; and
- 3. The batch does not contain contaminants unsafe for human consumption.⁺

[†]Tested analytes and limits were set by CV Sciences, Inc.

DB Labs Sample ID #:

*Actual analytical results obtained by DB Labs (Las Vegas, NV), CV Sciences' third-party testing laboratory.

Anresco Laboratories Sample ID #:

**Actual analytical results obtained by Anresco Laboratories (San Francisco, CA), CV Sciences' third-party testing laboratory.





CV SCIENCES, INC. 9530 Padgett Street, Suite 107 San Diego, CA 92126 **Certificate of Analysis**

Order No. 562224 Sample No. 1250943

SAMPLE INFORMATION

Description	FP-24-0099 plusCBD 15mg 90ct Softgel SKU 389 exp 02/26
Lot Number	A107400924
Category (Type)	Non-Inhalable Edible (Capsule)
Received	October 16, 2024

ANALYTICAL RESULTS

Analysis	Cannabinoid Profile (Non-Plant) 🛛 🔮 Pass
Instrument	Liquid Chromatography Diode Array Detector (LC-DAD)
Method	MF-CHEM-15
Analysis Date	October 16, 2024 to October 18, 2024

Cannabinoid	mg/g	%	mg/serving	mg/package	Labeled mg/ serving	% Difference (mg/ serving)	Status
Δ8-THC	ND	ND	ND	ND	-	-	-
Δ9-THC	<loq< td=""><td><loq< td=""><td><loq< td=""><td><loq< td=""><td>-</td><td>-</td><td>Pass</td></loq<></td></loq<></td></loq<></td></loq<>	<loq< td=""><td><loq< td=""><td><loq< td=""><td>-</td><td>-</td><td>Pass</td></loq<></td></loq<></td></loq<>	<loq< td=""><td><loq< td=""><td>-</td><td>-</td><td>Pass</td></loq<></td></loq<>	<loq< td=""><td>-</td><td>-</td><td>Pass</td></loq<>	-	-	Pass
Δ9-THCA	ND	ND	ND	ND	-	-	-
THCV	ND	ND	ND	ND	-	-	-
THCVA	ND	ND	ND	ND	-	-	-
CBD	37.14	3.714	15.98	1437.98	15	6.52	-
CBDA	ND	ND	ND	ND	-	-	-
CBC	ND	ND	ND	ND	-	-	-
CBCA	ND	ND	ND	ND	-	-	-
CBDV	<loq< td=""><td><loq< td=""><td><loq< td=""><td><loq< td=""><td>-</td><td>-</td><td>-</td></loq<></td></loq<></td></loq<></td></loq<>	<loq< td=""><td><loq< td=""><td><loq< td=""><td>-</td><td>-</td><td>-</td></loq<></td></loq<></td></loq<>	<loq< td=""><td><loq< td=""><td>-</td><td>-</td><td>-</td></loq<></td></loq<>	<loq< td=""><td>-</td><td>-</td><td>-</td></loq<>	-	-	-
CBG	<loq< td=""><td><loq< td=""><td><loq< td=""><td><loq< td=""><td>-</td><td>-</td><td>-</td></loq<></td></loq<></td></loq<></td></loq<>	<loq< td=""><td><loq< td=""><td><loq< td=""><td>-</td><td>-</td><td>-</td></loq<></td></loq<></td></loq<>	<loq< td=""><td><loq< td=""><td>-</td><td>-</td><td>-</td></loq<></td></loq<>	<loq< td=""><td>-</td><td>-</td><td>-</td></loq<>	-	-	-
CBGA	ND	ND	ND	ND	-	-	-
CBN	ND	ND	ND	ND	-	-	-
Total THC	<loq< td=""><td><loq< td=""><td><loq< td=""><td><loq< td=""><td>-</td><td>-</td><td>-</td></loq<></td></loq<></td></loq<></td></loq<>	<loq< td=""><td><loq< td=""><td><loq< td=""><td>-</td><td>-</td><td>-</td></loq<></td></loq<></td></loq<>	<loq< td=""><td><loq< td=""><td>-</td><td>-</td><td>-</td></loq<></td></loq<>	<loq< td=""><td>-</td><td>-</td><td>-</td></loq<>	-	-	-
Total CBD	37.14	3.714	15.98	1437.98	-	-	-
Total Cannabinoids	37.14	3.714	15.98	1437.98	-	-	-
Sum of Cannabinoids	37.14	3.714	15.98	1437.98	-	-	-
Serving Weight (g)	0.4302						
Package Weight (g)	38.72						

Comments

Reported by Anresco, Inc.



October 18, 2024

Reported results and measurements are based off of a calculated hypothetical weight using the ratio between filling weight and total capsule weight as per client instruction. Only the filling material was tested.

ND = None Detected LOD = Limit of Detection (0.1333 mg/g) LOQ = Limit of Quantitation (0.4000 mg/g) Total THC = $\Delta 8$ -THC + $\Delta 9$ -THC + (0.877 * THCA) Total CBD = CBD + (0.877 * CBDA) Total Cannabinoids = Σ (neutral cannabinoids) + [0.877 * Σ (acidic cannabinoids)]

If there are any questions with this report, please contact "compliance@anresco.com".

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave., San Francisco, CA 94124 Sample #: 1250943 Batch #: A107400924 page **1** of **1** Report ID: T-2



CV SCIENCES, INC. 9530 Padgett Street, Suite 107 San Diego, CA 92126 **Certificate of Analysis**

Order No. 562224 Sample No. 1250943

SAMPLE INFORMATION

Description	FP-24-0099 plusCBD 15mg 90ct Softgel SKU 389 exp 02/26
Lot Number	A107400924
Category (Type)	Non-Inhalable Edible (Capsule)
Received	October 16, 2024

ANALYTICAL RESULTS

Analysis	Pesticide Screen 🔮 Pass
Instrument	Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)
Method	MF-CHEM-13
Analysis Date	October 16, 2024 to October 18, 2024

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Abamectin	0.04/0.10	ND	0.3	Pass
Acephate	0.02/0.06	ND	5.0	Pass
Acequinocyl	0.04/0.10	ND	4.0	Pass
Acetamiprid	0.017/0.05	ND	5.0	Pass
Aldicarb	0.02/0.06	ND	0.02	Pass
Azoxystrobin	0.02/0.06	ND	40.0	Pass
Bifenazate	0.02/0.06	ND	5.0	Pass
Bifenthrin	0.04/0.10	ND	0.5	Pass
Boscalid	0.02/0.06	ND	10.0	Pass
Captan	0.2/0.6	ND	5.0	Pass
Carbaryl	0.02/0.06	ND	0.5	Pass
Carbofuran	0.017/0.05	ND	0.017	Pass
Chlorantraniliprole	0.02/0.06	ND	40.0	Pass
Chlordane	0.02/0.06	ND	0.02	Pass
Chlorfenapyr	0.02/0.06	ND	0.02	Pass
Chlorpyrifos	0.02/0.06	ND	0.02	Pass
Clofentezine	0.02/0.06	ND	0.5	Pass
Coumaphos	0.02/0.06	ND	0.02	Pass
Cyfluthrin	0.10/0.30	ND	1.0	Pass
Cypermethrin	0.10/0.30	ND	1.0	Pass
Daminozide	0.017/0.05	ND	0.017	Pass
DDVP (Dichlorvos)	0.013/0.04	ND	0.013	Pass
Diazinon	0.017/0.05	ND	0.2	Pass
Dimethoate	0.017/0.05	ND	0.017	Pass
Dimethomorph	0.017/0.05	ND	20.0	Pass
Ethoprop(hos)	0.02/0.06	ND	0.02	Pass
Etofenprox	0.02/0.06	ND	0.02	Pass
Etoxazole	0.02/0.06	ND	1.5	Pass
Fenhexamid	0.017/0.05	ND	10.0	Pass
Fenoxycarb	0.02/0.06	ND	0.02	Pass
Fenpyroximate	0.02/0.06	ND	2.0	Pass

If there are any questions with this report, please contact "compliance@anresco.com".

Anresco Laboratorieswww.anresco.comSample #: 1250943page 1 of 21375 Van Dyke Ave., San Francisco, CA 94124Batch #: A107400924Report ID: T-2



Certificate of Analysis

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Fipronil	0.02/0.06	ND	0.02	Pass
Flonicamid	0.02/0.06	ND	2.0	Pass
Fludioxonil	0.02/0.06	ND	30.0	Pass
Hexythiazox	0.02/0.06	ND	2.0	Pass
Imazalil	0.02/0.06	ND	0.02	Pass
Imidacloprid	0.02/0.06	ND	3.0	Pass
Kresoxim Methyl	0.02/0.06	ND	1.0	Pass
Malathion	0.017/0.05	ND	5.0	Pass
Metalaxyl	0.017/0.05	ND	15.0	Pass
Methiocarb	0.02/0.06	ND	0.02	Pass
Methomyl	0.013/0.04	ND	0.1	Pass
Methyl parathion	0.02/0.06	ND	0.02	Pass
Mevinphos	0.02/0.06	ND	0.02	Pass
Myclobutanil	0.02/0.06	ND	9.0	Pass
Naled	0.017/0.05	ND	0.5	Pass
Oxamyl	0.013/0.04	ND	0.2	Pass
Paclobutrazol	0.02/0.06	ND	0.02	Pass
Pentachloronitrobenzene	0.017/0.05	ND	0.2	Pass
Permethrins	0.10/0.30	ND	20.0	Pass
Phosmet	0.02/0.06	ND	0.2	Pass
Piperonyl Butoxide	0.017/0.05	ND	8.0	Pass
Prallethrin	0.04/0.10	ND	0.4	Pass
Propiconazole	0.02/0.06	ND	20.0	Pass
Propoxur	0.013/0.04	ND	0.013	Pass
Pyrethrins	0.15/0.50	ND	1.0	Pass
Pyridaben	0.017/0.05	ND	3.0	Pass
Spinetoram	0.02/0.06	ND	3.0	Pass
Spinosad	0.02/0.06	ND	3.0	Pass
Spiromesifen	0.04/0.10	ND	12.0	Pass
Spirotetramat	0.02/0.06	ND	13.0	Pass
Spiroxamine	0.017/0.05	ND	0.017	Pass
Tebuconazole	0.02/0.06	0.079	2.0	Pass
Thiacloprid	0.013/0.04	ND	0.013	Pass
Thiamethoxam	0.02/0.06	ND	4.5	Pass
Trifloxystrobin	0.02/0.06	<loq (0.025)<="" td=""><td>30.0</td><td>Pass</td></loq>	30.0	Pass

Reported by **Anresco, Inc.**



October 18, 2024

ND = None Detected LOD = Limit of Detection LOQ = Limit of Quantitation

If there are any questions with this report, please contact "compliance@anresco.com".

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave., San Francisco, CA 94124 Sample #: 1250943 Batch #: A107400924 page**2** of **2** Report ID: T-2



CV SCIENCES, INC. 9530 Padgett Street, Suite 107 San Diego, CA 92126 Order No. 562224 Sample No. 1250943

Certificate of Analysis

SAMPLE INFORMATION

Description	FP-24-0099 plusCBD 15mg 90ct Softgel SKU 389 exp 02/26
Lot Number	A107400924
Category (Type)	Non-Inhalable Edible (Capsule)
Received	October 16, 2024

ANALYTICAL RESULTS

Analysis	Residual Solvent Screen 🔮 Pass
Instrument	Gas Chromatography Mass Spectrometry (GC/MS)
Method	MF-CHEM-32
Analysis Date	October 16, 2024 to October 18, 2024

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
1,2-Dichloroethane	0.5/0.5	ND	1	Pass
Acetone	57/200	ND	5000	Pass
Acetonitrile	56/200	ND	410	Pass
Benzene	0.5/0.5	ND	1	Pass
n-Butane	45/200	ND	5000	Pass
Chloroform	0.5/0.5	ND	1	Pass
Ethanol	37/200	ND	5000	Pass
Ethyl acetate	38/200	ND	5000	Pass
Ethyl ether	37/200	ND	5000	Pass
Ethylene oxide	0.1/0.5	ND	1	Pass
n-Heptane	135/200	ND	5000	Pass
n-Hexane	49/200	ND	290	Pass
Isopropyl alcohol	57/200	ND	5000	Pass
Methanol	37/200	ND	3000	Pass
Methylene chloride	0.1/0.5	ND	1	Pass
n-Pentane	37/200	ND	5000	Pass
Propane	72/200	ND	5000	Pass
Toluene	49/200	ND	890	Pass
Total xylenes (ortho-, meta-, para-)	58/200	ND	2170	Pass
Trichloroethylene	0.5/0.5	ND	1	Pass

Reported by Anresco, Inc.



October 18, 2024

ND = None Detected LOD = Limit of Detection LOQ = Limit of Quantitation

If there are any questions with this report, please contact "compliance@anresco.com".

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave., San Francisco, CA 94124 page**1** of **1** Report ID: T-2



CV SCIENCES, INC. 9530 Padgett Street, Suite 107 San Diego, CA 92126 **Certificate of Analysis**

Order No. 562224 Sample No. 1250943

SAMPLE INFORMATION

Description	FP-24-0099 plusCBD 15mg 90ct Softgel SKU 389 exp 02/26
Lot Number	A107400924
Category (Type)	Non-Inhalable Edible (Capsule)
Received	October 16, 2024
	ANALYTICAL RESULTS

Analysis	Mycotoxins Screen 🔮 Pass
Instrument	Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)
Method	MF-CHEM-13
Analysis Date	October 16, 2024 to October 18, 2024

Analyte	LOD/LOQ (ppb)	Findings (ppb)	Limit (ppb)	Status
Aflatoxin B1	2/5	ND	-	-
Aflatoxin B2	2/5	ND	-	-
Aflatoxin G1	2/5	ND	-	-
Aflatoxin G2	2/5	ND	-	-
Total Aflatoxins	8/20	ND	20	Pass
Ochratoxin A	6/18	ND	20	Pass

Reported by **Anresco, Inc.**



October 18, 2024

ND = None Detected LOD = Limit of Detection LOQ = Limit of Quantitation

If there are any questions with this report, please contact "compliance@anresco.com".

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave., San Francisco, CA 94124



October 22, 2024

CV SCIENCES, INC. 9530 Padgett Street, Suite 107 San Diego, CA 92126 Order No. 562224 Sample No. 1250943

Certificate of Analysis

SAMPLE INFORMATION

 Description
 FP-24-0099 plusCBD 15mg 90ct Softgel SKU 389 exp 02/26

 Lot Number
 A107400924

 Received
 October 16, 2024

ANALYTICAL RESULTS

Analysis Date October 16, 2024 to October 22, 2024

Findings	Analysis	Results	Method
	Standard Plate Count	<10 cfu/g	FDA BAM
	Yeast	<10 cfu/g	FDA BAM
	Mold	<10 cfu/g	FDA BAM
	Coliforms	<10 cfu/g	FDA BAM - ECC AGAR
	Escherichia coli	<10 cfu/g	FDA BAM - ECC AGAR
	Salmonella	Negative /25g	MF-MICRO-11 (AOAC 2016.01)
	Staph aureus	Negative /25g	USP <62>

Reported by **Anresco, Inc.**



If there are any questions with this report, please contact "compliance@anresco.com".

Tel: 415 822 1100 Fax: 415 822 6615 Report ID: S-1

page 1 of 1

This document is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential or protected from disclosure under applicable law. If you have received this document in error, please immediately notify us and return it to the address listed above.



Certificate of Analysis

October 18, 2024

CV SCIENCES, INC. 9530 Padgett Street, Suite 107 San Diego, CA 92126

Order No. 562224 Sample No. 1250943

SAMPLE INFORMATION

Description	FP-24-0099 plusCBD 15mg 90ct Softgel SKU 389 exp 02/26
Lot Number	A107400924
Category (Type)	Non-Inhalable Edible (Capsule)
Received	October 16, 2024

ANALYTICAL RESULTS

Analysis	Heavy Metals 🔮 Pass
Instrument	Inductively Coupled Plasma Mass Spectrometry (ICP-MS)
Method	MF-CHEM-16
Analysis Date	October 16, 2024 to October 18, 2024

Analyte	LOD/LOQ (µg/g)	Findings (µg/g)	Limit (µg/g)	Status
Arsenic	0.02/0.05	<loq< td=""><td>1.5</td><td>Pass</td></loq<>	1.5	Pass
Cadmium	0.02/0.05	ND	0.5	Pass
Mercury	0.02/0.05	ND	3	Pass
Lead	0.02/0.125	ND	0.5	Pass

Reported by **Anresco, Inc.**



Senior Chemist October 18, 2024 ND = None Detected LOD = Limit of Detection LOQ = Limit of Quantitation

If there are any questions with this report, please contact "compliance@anresco.com".

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave., San Francisco, CA 94124 page **1** of **1** Report ID: T-2

DocuSign

Certificate Of Completion Envelope Id: 11DA3FBBCC1C4B5FA7BE5E03E92AE270 Status: Completed Subject: FP-24-0099 plusCBD 15mg 90ct Softgel SKU 389 exp 02/26 A107400924 Source Envelope: Document Pages: 9 Signatures: 1 Envelope Originator: Certificate Pages: 1 Initials: 0 Vandana Kothari AutoNav: Enabled vandana.kothari@cvsciences.com EnvelopeId Stamping: Enabled IP Address: 64.207.219.136 Time Zone: (UTC-08:00) Pacific Time (US & Canada) **Record Tracking** Status: Original Holder: Vandana Kothari Location: DocuSign 10/23/2024 11:46:06 AM vandana.kothari@cvsciences.com Signer Events Timestamp Signature Vandana Kothari Sent: 10/23/2024 11:46:45 AM Vandana kothari vandana.kothari@cvsciences.com Viewed: 10/23/2024 11:47:10 AM DIRECTOR OF QUALITY Signed: 10/23/2024 11:47:49 AM CV Sciences - Part 11 Signature Adoption: Pre-selected Style Security Level: Email, Account Authentication Signature ID: (Required) 87A410FF-F032-4873-8900-BEED0868E359 Using IP Address: 75.85.176.253 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document **Electronic Record and Signature Disclosure:** Not Offered via DocuSign

In Person Signer Events	Signature	Timestamp
Editor Delivery Events	Status	Timestamp
Agent Delivery Events	Status	Timestamp
Intermediary Delivery Events	Status	Timestamp
Certified Delivery Events	Status	Timestamp
Carbon Copy Events	Status	Timestamp
Witness Events	Signature	Timestamp
	• . 9	
Notary Events	Signature	Timestamp
	-	
Notary Events	Signature	Timestamp
Notary Events Envelope Summary Events	Signature Status	Timestamp Timestamps
Notary Events Envelope Summary Events Envelope Sent	Signature Status Hashed/Encrypted	Timestamp Timestamps 10/23/2024 11:46:45 AM
Notary Events Envelope Summary Events Envelope Sent Certified Delivered	Signature Status Hashed/Encrypted Security Checked	Timestamp 10/23/2024 11:46:45 AM 10/23/2024 11:47:10 AM